What is ABBV revenue?

AbbVie Inc. (ABBV) reported $66.01B of revenue for the twelve months ended Sep 30, 2026. That is up 10.7% from the year before. Revenue for fiscal 2025 was $61.16B.

Yes. AbbVie Inc. earned $10.34B in net income for the twelve months ended Sep 30, 2026, a net margin of 15.7%.

How much cash and debt does ABBV have?

AbbVie Inc. reported $10.77B in cash and cash equivalents and $72.23B of debt on its most recent balance sheet in SEC filings.

How fast is ABBV revenue growing?

AbbVie Inc.'s revenue changed +8.6% in fiscal 2025, to $61.16B. Its compound annual growth rate was +6.0% over 5 years and +10.3% over 10 years.

What is ABBV gross margin?

AbbVie Inc.'s gross profit was $48.67B on $66.01B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 73.7%.

What is ABBV free cash flow?

AbbVie Inc. generated $18.87B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $20.09B less capital expenditures.

What is ABBV earnings per share?

Diluted earnings per share were $5.81 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.

When did ABBV last report financial results?

The latest statements here come from AbbVie Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.

Where does this ABBV financial data come from?

Quantisnow builds these statements from the structured XBRL data AbbVie Inc. files with the SEC. It is provided for information only and is not investment advice.

Financials · ABBV

AbbVie Inc. (ABBV) financials

For the twelve months ended Sep 30, 2026, AbbVie Inc. reported $66.01B of revenue and $10.34B of net income.

Revenue, TTM: $66.01B
Revenue growth, YoY: +10.7%
Net income, TTM: $10.34B
Net income growth, YoY: +333.1%
Net margin: 15.7%
Free cash flow, TTM: $18.87B
EPS, diluted, TTM: $5.81
Cash: $10.77B
Total debt: $72.23B
P/E: 49.79
P/S: 7.80
Market cap: $514.92B

Annual revenue$61.16B

FY2016FY2025

Annual net income$4.23B

FY2016FY2025

Annual free cash flow$17.82B

FY2016FY2025

ABBV revenue and earnings growth

ABBV revenueQ3 2026$17.40B

Quarter YoY: +10.3%
QoQ: +2.4%
FY YoY: +8.6%
5Y CAGR: +6.0%
10Y CAGR: +10.3%

ABBV revenue was $17.40B in fiscal Q3 2026 (ended Sep 30, 2026), up 10.3% from a year earlier and up 2.4% from the prior quarter. For the full fiscal 2025 it was $61.16B, up 8.6% from fiscal 2024. Compound annual growth was +6.0% over 5 years and +10.3% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

ABBV net incomeQ3 2026$4.22B

Quarter YoY: 23x
QoQ: +16.7%
FY YoY: -1.2%
5Y CAGR: -1.7%
10Y CAGR: -1.9%

ABBV net income was $4.22B in fiscal Q3 2026 (ended Sep 30, 2026), up about 23-fold from a year earlier and up 16.7% from the prior quarter. For the full fiscal 2025 it was $4.23B, down 1.2% from fiscal 2024. Compound annual growth was -1.7% over 5 years and -1.9% over 10 years. It rose in 5 of the last 10 fiscal years.

ABBV EPSQ3 2026$2.37

Quarter YoY: 24x
QoQ: +16.7%
FY YoY: -1.3%
5Y CAGR: -2.8%
10Y CAGR: -2.8%

ABBV diluted EPS was $2.37 in fiscal Q3 2026 (ended Sep 30, 2026), up about 24-fold from a year earlier and up 16.7% from the prior quarter. For the full fiscal 2025 it was $2.36, down 1.3% from fiscal 2024. Compound annual growth was -2.8% over 5 years and -2.8% over 10 years.

ABBV free cash flowQ3 2026$7.30B

Quarter YoY: +10.0%
QoQ: +134.6%
FY YoY: -0.1%
5Y CAGR: +1.2%
10Y CAGR: +9.8%

ABBV free cash flow was $7.30B in fiscal Q3 2026 (ended Sep 30, 2026), up 10.0% from a year earlier and up 134.6% from the prior quarter. For the full fiscal 2025 it was $17.82B, down 0.1% from fiscal 2024. Compound annual growth was +1.2% over 5 years and +9.8% over 10 years. It rose in 5 of the last 10 fiscal years.

Export CSV

Income statement

Income statement
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue	$61.16B	$56.33B	$54.32B	$58.05B	$56.20B	$45.80B	$33.27B	$32.75B	$28.22B	$25.64B
Cost of revenue	$18.20B	$16.90B	$20.41B	$17.41B	$17.45B	$15.39B	$7.44B	$7.72B	$7.04B	$5.83B
Gross profit	$42.96B	$39.43B	$33.90B	$40.64B	$38.75B	$30.42B	$25.83B	$25.04B	$21.17B	$19.81B
Research and development	$9.10B	$12.79B	$7.67B	$6.51B	$6.92B	$6.38B	$6.41B	$10.33B	$5.01B	$4.38B
Selling, general and admin	$14.01B	$14.75B	$12.87B	$15.26B	$12.35B	$11.30B	$6.94B	$7.40B	$6.29B	$5.88B
Operating income	$15.07B	$9.14B	$12.76B	$18.12B	$17.92B	$11.36B	$12.98B	$6.38B	$9.54B	$9.34B
Interest expense	$2.89B	$2.81B	$2.22B	$2.23B	$2.42B	$2.45B	$1.78B	$1.35B	$1.15B	$1.05B
Pre-tax income	$6.60B	$3.72B	$6.25B	$13.48B	$12.99B	$3.40B	$8.43B	$5.20B	$7.73B	$7.88B
Income tax	$2.36B	-$570.00M	$1.38B	$1.63B	$1.44B	-$1.22B	$544.00M	-$490.00M	$2.42B	$1.93B
Net income	$4.23B	$4.28B	$4.86B	$11.84B	$11.54B	$4.62B	$7.88B	$5.69B	$5.31B	$5.95B
EPS, basic	$2.37	$2.40	$2.73	$6.65	$6.48	$2.73	$5.30	$3.67	$3.31	$3.65
EPS, diluted	$2.36	$2.39	$2.72	$6.63	$6.45	$2.72	$5.28	$3.66	$3.30	$3.63
Diluted shares	1.77B	1.77B	1.77B	1.78B	1.78B	1.67B	1.48B	1.55B	1.60B	1.63B

Balance sheet

Balance sheet
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Cash and equivalents	$5.23B	$5.52B	$12.81B	$9.20B	$9.75B	$8.45B	$39.92B	$7.29B	$9.30B	$5.10B
Short-term investments	$28.00M	$31.00M	$2.00M	$28.00M	$84.00M	$30.00M	$0	$772.00M	$486.00M	$1.32B
Receivables	$12.59B	$10.92B	$11.15B	$11.25B	$9.98B	$8.82B	$5.43B	$5.38B	$5.09B	$4.76B
Inventory	$4.95B	$4.18B	$4.10B	$3.58B	$3.13B	$3.31B	$1.81B	$1.60B	$1.60B	$1.44B
Current assets	$29.06B	$25.58B	$33.00B	$28.46B	$27.93B	$24.17B	$49.52B	$16.95B	$21.22B	$16.19B
Goodwill	$35.64B	$34.96B	$32.29B	$32.16B	$32.38B	$33.12B	$15.60B	$15.66B	$15.79B	$15.42B
Total assets	$133.96B	$135.16B	$134.71B	$138.81B	$146.53B	$150.56B	$89.11B	$59.35B	$70.79B	$66.10B
Current liabilities	$43.29B	$38.75B	$37.84B	$29.54B	$35.19B	$28.66B	$15.59B	$17.24B	$16.64B	$9.78B
Short-term debt	$2.50B	$0	$0	$1.00M	$14.00M	$34.00M	$0	$3.70B	$400.00M	$377.00M
Long-term debt	$58.94B	$60.34B	$52.19B	$59.13B	$64.19B	$77.55B	$62.98B	$35.00B	$30.95B	$36.44B
Total debt	$61.44B	$60.34B	$52.19B	$59.14B	$64.20B	$77.59B	$62.98B	$38.70B	$31.35B	$36.82B
Total liabilities	$137.19B	$131.80B	$124.31B	$121.52B	$131.09B	$137.47B	$97.29B	$67.80B	$65.69B	-
Shareholders' equity	-$3.27B	$3.36B	$10.40B	$17.29B	$15.44B	$13.10B	-$8.17B	-$8.45B	$5.10B	$4.64B

Cash flow

Cash flow
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Operating cash flow	$19.03B	$18.81B	$22.84B	$24.94B	$22.78B	$17.59B	$13.32B	$13.43B	$9.96B	$7.04B
Capital expenditures	$1.21B	$974.00M	$777.00M	$695.00M	$787.00M	$798.00M	$552.00M	$638.00M	$529.00M	$479.00M
Free cash flow	$17.82B	$17.83B	$22.06B	$24.25B	$21.99B	$16.79B	$12.77B	$12.79B	$9.43B	$6.56B
Investing cash flow	-$6.64B	-$20.82B	-$2.01B	-$623.00M	-$2.34B	-$37.56B	$596.00M	-$1.01B	-$274.00M	-$6.07B
Financing cash flow	-$12.72B	-$5.21B	-$17.22B	-$24.80B	-$19.04B	-$11.50B	$18.71B	-$14.40B	-$5.51B	-$3.93B
Dividends paid	$11.66B	$11.03B	$10.54B	$10.04B	$9.26B	$7.72B	$6.37B	$5.58B	$4.11B	$3.72B
Share repurchases	$980.00M	$1.71B	$1.97B	$1.49B	$934.00M	$978.00M	$629.00M	$12.01B	$1.41B	$6.03B
Stock-based compensation	$955.00M	$911.00M	$747.00M	$671.00M	$692.00M	$753.00M	$430.00M	$421.00M	$365.00M	$353.00M

Key ratios

Key ratios
Line item	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021	FY2020 Dec 31, 2020	FY2019 Dec 31, 2019	FY2018 Dec 31, 2018	FY2017 Dec 31, 2017	FY2016 Dec 31, 2016
Revenue growth, YoY	8.6%	3.7%	-6.4%	3.3%	22.7%	37.7%	1.6%	16.1%	10.1%	12.2%
Net income growth, YoY	-1.2%	-12.0%	-58.9%	2.5%	150.0%	-41.4%	38.6%	7.1%	-10.8%	15.7%
EPS growth, YoY	-1.3%	-12.1%	-59.0%	2.8%	137.1%	-48.5%	44.3%	10.9%	-9.1%	16.0%
Gross margin	70.2%	70.0%	62.4%	70.0%	69.0%	66.4%	77.6%	76.4%	75.0%	77.3%
Operating margin	24.6%	16.2%	23.5%	31.2%	31.9%	24.8%	39.0%	19.5%	33.8%	36.4%
Net margin	6.9%	7.6%	9.0%	20.4%	20.5%	10.1%	23.7%	17.4%	18.8%	23.2%
Free cash flow margin	29.1%	31.7%	40.6%	41.8%	39.1%	36.7%	38.4%	39.0%	33.4%	25.6%
Return on equity	-	127.2%	46.8%	68.5%	74.8%	35.2%	-	-	104.2%	128.4%
Return on assets	3.2%	3.2%	3.6%	8.5%	7.9%	3.1%	8.8%	9.6%	7.5%	9.0%
Current ratio	0.67	0.66	0.87	0.96	0.79	0.84	3.18	0.98	1.28	1.65
Debt to equity	-	17.94	5.02	3.42	4.16	5.92	-	-	6.15	7.94

Income statement

Income statement
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue	$17.40B	$16.99B	$15.00B	$16.62B	$15.78B	$15.42B	$13.34B	$15.10B	$14.46B	$14.46B	$12.31B	$14.30B
Cost of revenue	$4.29B	$4.29B	$4.22B	$4.55B	$5.30B	$4.35B	$4.00B	$4.40B	$4.21B	$4.20B	$4.09B	$5.70B
Gross profit	$13.12B	$12.70B	$10.78B	$12.07B	$10.47B	$11.08B	$9.34B	$10.71B	$10.25B	$10.26B	$8.22B	$8.60B
Research and development	$2.57B	$2.34B	$2.47B	$2.58B	$2.32B	$2.13B	$2.07B	$6.77B	$2.13B	$1.95B	$1.94B	$1.93B
Selling, general and admin	$4.09B	$3.63B	$3.58B	$3.90B	$3.57B	$3.25B	$3.29B	$3.85B	$4.21B	$3.38B	$3.31B	$3.19B
Operating income	$6.27B	$6.43B	$3.99B	$4.54B	$1.90B	$4.89B	$3.73B	-$1.49B	$3.83B	$4.00B	$2.80B	$3.19B
Interest expense	$802.00M	$746.00M	$717.00M	$714.00M	$739.00M	$740.00M	$700.00M	$702.00M	$720.00M	$726.00M	$660.00M	$564.00M
Pre-tax income	$4.83B	$4.28B	$1.04B	$2.67B	$714.00M	$1.55B	$1.66B	-$2.27B	$2.08B	$2.15B	$1.75B	$1.21B
Income tax	$609.00M	$662.00M	$342.00M	$853.00M	$526.00M	$613.00M	$372.00M	-$2.25B	$520.00M	$773.00M	$383.00M	$388.00M
Net income	$4.22B	$3.61B	$695.00M	$1.82B	$186.00M	$938.00M	$1.29B	-$22.00M	$1.56B	$1.37B	$1.37B	$822.00M
EPS, basic	$2.38	$2.04	$0.39	$1.02	$0.10	$0.52	$0.72	-$0.02	$0.88	$0.77	$0.77	$0.46
EPS, diluted	$2.37	$2.03	$0.39	$1.02	$0.10	$0.52	$0.72	-$0.02	$0.88	$0.77	$0.77	$0.46
Diluted shares	1.77B	1.77B	1.77B	-	1.77B	1.77B	1.77B	-	1.77B	1.77B	1.77B	-

Balance sheet

Balance sheet
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Cash and equivalents	$10.77B	$6.57B	$9.39B	$5.23B	$5.63B	$6.47B	$5.17B	$5.52B	$7.26B	$13.13B	$18.07B	$12.81B
Short-term investments	-	-	-	$28.00M	$42.00M	$0	$1.00M	$31.00M	$28.00M	$27.00M	$2.00M	$2.00M
Receivables	$13.51B	$13.82B	$12.48B	$12.59B	$12.77B	$12.64B	$12.48B	$10.92B	$11.47B	$11.72B	$11.95B	$11.15B
Inventory	$5.30B	$5.13B	$5.05B	$4.95B	$4.94B	$4.96B	$4.53B	$4.18B	$4.45B	$4.22B	$4.25B	$4.10B
Current assets	$37.48B	$33.67B	$33.53B	$29.06B	$28.54B	$29.26B	$27.68B	$25.58B	$27.79B	$33.82B	$38.87B	$33.00B
Goodwill	$37.80B	$35.52B	$35.57B	$35.64B	$35.63B	$35.64B	$35.28B	$34.96B	$35.30B	$33.39B	$33.43B	$32.29B
Total assets	$147.68B	$135.12B	$136.46B	$133.96B	$133.90B	$137.18B	$136.16B	$135.16B	$143.42B	$141.94B	$148.87B	$134.71B
Current liabilities	$43.10B	$41.64B	$42.10B	$43.29B	$39.39B	$39.77B	$36.40B	$38.75B	$43.06B	$41.91B	$41.52B	$37.84B
Short-term debt	$0	$0	$0	$2.50B	$3.79B	$5.56B	$1.59B	$0	-	-	$3.00M	$0
Long-term debt	$72.23B	$62.48B	$64.53B	$58.94B	$62.97B	$62.96B	$64.53B	$60.34B	$58.51B	$58.05B	$63.80B	$52.19B
Total debt	$72.23B	$62.48B	$64.53B	$61.44B	$66.76B	$68.52B	$66.12B	$60.34B	$58.51B	$58.05B	$63.81B	$52.19B
Total liabilities	$152.22B	$141.00B	$143.07B	$137.19B	$136.50B	$137.32B	$134.70B	$131.80B	$137.35B	$135.12B	$140.83B	$124.31B
Shareholders' equity	-$4.58B	-$5.89B	-$6.61B	-$3.27B	-$2.60B	-$138.00M	$1.46B	$3.36B	$6.07B	$6.82B	$8.05B	$10.40B

Cash flow

Cash flow
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Operating cash flow	$7.61B	$3.44B	$3.83B	$5.22B	$7.02B	$5.15B	$1.64B	$7.05B	$5.45B	$2.27B	$4.04B	$4.75B
Capital expenditures	$301.00M	$322.00M	$265.00M	$329.00M	$381.00M	$269.00M	$235.00M	$291.00M	$249.00M	$241.00M	$193.00M	$205.00M
Free cash flow	$7.30B	$3.11B	$3.56B	$4.89B	$6.64B	$4.88B	$1.40B	$6.76B	$5.20B	$2.03B	$3.85B	$4.55B
Investing cash flow	-$10.21B	-$1.20B	-$574.00M	-$1.46B	-$3.26B	-$1.18B	-$735.00M	-$1.87B	-$8.26B	-$1.10B	-$9.59B	-$800.00M
Financing cash flow	$6.82B	-$5.05B	$919.00M	-$4.17B	-$4.59B	-$2.71B	-$1.26B	-$6.86B	-$3.07B	-$6.10B	$10.82B	-$4.45B
Dividends paid	$3.07B	$3.07B	$3.09B	$2.91B	$2.91B	$2.91B	$2.92B	$2.75B	$2.75B	$2.75B	$2.77B	$2.63B
Share repurchases	$5.00M	$9.00M	$1.49B	$3.00M	$4.00M	$12.00M	$961.00M	$358.00M	$17.00M	$9.00M	$1.32B	$3.00M
Stock-based compensation	$160.00M	$166.00M	$444.00M	$157.00M	$209.00M	$179.00M	$410.00M	$164.00M	$181.00M	$218.00M	$348.00M	$125.00M

Key ratios

Key ratios
Line item	Q3 2026 Sep 30, 2026	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q2 2024 Jun 30, 2024	Q1 2024 Mar 31, 2024	Q4 2023 Dec 31, 2023
Revenue growth, YoY	10.3%	10.2%	12.4%	10.0%	9.1%	6.6%	8.4%	5.6%	3.8%	4.3%	0.7%	-5.4%
Net income growth, YoY	2167.7%	285.2%	-46.0%	-	-88.1%	-31.5%	-6.1%	-	-12.2%	-32.3%	472.8%	-66.8%
EPS growth, YoY	2270.0%	290.4%	-45.8%	-	-88.6%	-32.5%	-6.5%	-	-12.0%	-32.5%	492.3%	-66.7%
Gross margin	75.4%	74.7%	71.9%	72.6%	66.4%	71.8%	70.0%	70.9%	70.9%	70.9%	66.7%	60.1%
Operating margin	36.0%	37.9%	26.6%	27.3%	12.1%	31.7%	28.0%	-9.9%	26.5%	27.6%	22.7%	22.3%
Net margin	24.2%	21.3%	4.6%	10.9%	1.2%	6.1%	9.6%	-0.1%	10.8%	9.5%	11.1%	5.7%
Free cash flow margin	42.0%	18.3%	23.8%	29.4%	42.1%	31.7%	10.5%	44.7%	35.9%	14.0%	31.3%	31.8%
Current ratio	0.87	0.81	0.80	0.67	0.72	0.74	0.76	0.66	0.65	0.81	0.94	0.87
Debt to equity	-	-	-	-	-	-	45.23	17.94	9.64	8.51	7.93	5.02

Source: XBRL data AbbVie Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ABBV peers

Company	Revenue	Growth	Net income	Net margin	Market cap
ABBV	$66.01B	+10.7%	$10.34B	15.7%	$514.92B
LLYEli Lilly and Company	$86.46B	+45.5%	$27.58B	31.9%	$1.27T
JNJJohnson & Johnson	$99.33B	+7.8%	$16.09B	16.2%	$664.95B
NVSNovartis AG	$54.53B	+8.4%	$13.98B	25.6%	$310.17B
AMGNAmgen Inc.	$38.90B	+8.2%	$9.39B	24.1%	$249.05B
ABTAbbott Laboratories	$48.23B	+10.0%	$4.70B	9.7%	$190.39B
PFEPfizer Inc.	$63.63B	+1.3%	$4.03B	6.3%	$167.49B
BMYBristol-Myers Squibb Company	$50.03B	+4.2%	$9.24B	18.5%	$127.01B
SNYSanofi	€43.63B	+6.2%	€7.81B	17.9%	$114.71B

ABBV FAQ

9 questions

What is ABBV revenue?
AbbVie Inc. (ABBV) reported $66.01B of revenue for the twelve months ended Sep 30, 2026. That is up 10.7% from the year before. Revenue for fiscal 2025 was $61.16B.
Is ABBV profitable?
Yes. AbbVie Inc. earned $10.34B in net income for the twelve months ended Sep 30, 2026, a net margin of 15.7%.
How much cash and debt does ABBV have?
AbbVie Inc. reported $10.77B in cash and cash equivalents and $72.23B of debt on its most recent balance sheet in SEC filings.
How fast is ABBV revenue growing?
AbbVie Inc.'s revenue changed +8.6% in fiscal 2025, to $61.16B. Its compound annual growth rate was +6.0% over 5 years and +10.3% over 10 years.
What is ABBV gross margin?
AbbVie Inc.'s gross profit was $48.67B on $66.01B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 73.7%.
What is ABBV free cash flow?
AbbVie Inc. generated $18.87B of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $20.09B less capital expenditures.
What is ABBV earnings per share?
Diluted earnings per share were $5.81 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
When did ABBV last report financial results?
The latest statements here come from AbbVie Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
Where does this ABBV financial data come from?
Quantisnow builds these statements from the structured XBRL data AbbVie Inc. files with the SEC. It is provided for information only and is not investment advice.